Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AB 205

Next Previous
Drug Profile

AB 205

Alternative Names: AB-205; AB-205 + HDT-ASCT; AB-205 + mdUCBT; AB-205-L; AB-205-S; AB-207; E-CEL UVEC cells; Engineered human umbilical vein endothelial cells – Angiocrine Bioscience; Universal E-CEL® Cell Therapy

Latest Information Update: 05 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Angiocrine Bioscience
  • Developer Angiocrine Bioscience; Weill Cornell Medical College
  • Class Antineoplastics; Chemoprotectants; Gene therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chemotherapy-induced damage
  • New Molecular Entity No

Highest Development Phases

  • Phase III Chemotherapy-induced damage
  • Phase I/II Gastrointestinal disorders; Leukaemia; Myelodysplastic syndromes
  • Phase I Fissure in ano; Rectal fistula; Shoulder injuries
  • Research Soft tissue injuries
  • Discontinued Sickle cell anaemia

Most Recent Events

  • 31 Jul 2024 Phase-I clinical trials in Fissure in ano in USA (Transdermal), before July 2024 (NCT06456073)
  • 13 Jun 2024 Weill Medical College of Cornell University plans phase-Ib trial for Fissure in ano in USA (Transdermal, injection) in June 2024 (NCT06456073)
  • 24 Jan 2024 Angiocrine Bioscience terminates a phase-III clinical trials in Chemotherapy-induced damage in USA (IV), as interim analysis showed lack of efficacy (NCT05181540)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top